leronlimab + antiretroviral therapy

**Leronlimab + antiretroviral therapy** is a combination regimen for the treatment of HIV-1 infection in patients with resistance to standard agents. Leronlimab is a humanized monoclonal antibody that binds with high affinity to the C-C chemokine receptor type 5 (CCR5) found on certain immune cell surfaces, thereby preventing HIV from entering CD4+ T-cells and interfering with viral replication. The combination is designed for salvage therapy or to maintain viral suppression in treatment-experienced adult patients, particularly those infected with CCR5-tropic HIV. Clinical trials have shown significant reductions in HIV-1 viral load and sustained virologic suppression when leronlimab is administered alongside optimized background ART. Leronlimab is administered via subcutaneous injection, typically weekly, and offers advantages such as less frequent dosing, no drug-related serious adverse events, and a high barrier to viral resistance. The combination is not approved but is in advanced clinical development.

Other names

leronlimab + ARTleronlimab + highly active antiretroviral therapyleronlimab + HAART